Alexion Pharmaceuticals, Inc. (ALXN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN)

ALXN 182.50

0.0%

Jul 28 4:00 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Doc Bones	10/23/2008 9:29:15 AM
	of 824

Alexion Q3 profit beats Street, raises 2008 rev view Thu Oct 23, 2008 8:57am EDT Q3 non-GAAP EPS $0.29 Analysts were expecting $0.04/shr Q3 revenue $76.5 mln versus $21.8 mln a year ago Raises FY 2008 revenue view Shares rise 4 pct in trading before the bell Oct 23 (Reuters) - Alexion Pharmaceuticals Inc (ALXN.O) posted quarterly results that topped market estimates as revenue from its genetic disorder drug more than tripled, and it raised its 2008 revenue view, sending its shares up 4 percent. The pharmaceutical company derives all of its revenue from its drug Soliris, which treats paroxysmal nocturnal hemoglobinuria (PNH). The rare genetic disorder can lead to anemia, fatigue, pain and difficulty in breathing. Alexion expects worldwide Soliris net product sales of $256 million to $258 million for the full year 2008, up from its previous outlook of $235 million to $245 million. Analysts on average expected $248 million, according to Reuters Estimates. The company said it expects to report a profit for both the fourth quarter and the full year 2008. Shares of Alexion were trading at $41.25 before the bell. They closed at $39.66 Wednesday on Nasdaq. (Reporting by Jennifer Robin Raj in Bangalore; Editing by Deepak Kannan) us.rd.yahoo.comhttp://www.reuters.com/legacyArticle?duid=mtfh77476_2008-10-23_12-57-55_bng297095_newsml&rpc=44&type=marketsNews

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next